Last, but not least, the low rates of venous thromboembolism in the PALOMA trial underlines the importance of personalized risk evaluation as a baseline and prompt administration of anticoagulants in patients with EGFR-mutant NSCLC. This evidence concerns the gene EGFR and venous thromboembolism.